



Our STN: BL 125690/97

SUPPLEMENT APPROVAL

April 20, 2026

Merck Sharp & Dohme LLC
Attention: Kristen Milenki, PharmD
351 N. Sumneytown Pike
P.O. Box 1000
UG2D-68
North Wales, PA 19454-2505

Dear Dr. Milenki:

We have approved your request received June 20, 2025, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Ebola Zaire Vaccine, Live (ERVEBO), to update the package insert to include safety and immunogenicity data from the Phase 2 study, V920-15, that evaluated the safety and immunogenicity of ERVEBO in HIV-infected adults and adolescents.

The review of this supplement was associated with the following National Clinical Trial (NCT) number: NCT03031912.

LABELING

We hereby approve the draft content of labeling: Package Insert submitted under amendment 15, dated April 16, 2026.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert submitted on April 16, 2026. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125690 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include the information contained in the above-referenced supplement in your BLA file.

Sincerely,

Andrea Hulse, MD, for
Acting Division Director
Division of Clinical and Toxicology Review
Office of Vaccine Research and Review
Center for Biologics Evaluation and Research